new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 Receptor Agonists and Research

It may provide an alternative option if approved

National Institute of Health (NIH), after analyzing weights and cardiovascular, metabolic risk factors a year after suspending the Wegovy treatment, patients regained two-thirds of the lost weight on average, and their cardiovascular, metabolic risk factors also returned to similar levels to changed weights

Treatment discontinuation due to adverse events occurred in approximately 5-10% of orforglipron-treated participants

Conclusion: Choosing Miralax or Metamucil If you're trying to safely manage GLP-1 Constipation , there are excellent, highly effective generic alternatives that use PEG 3350 instead of fiber